Nucleai

Home
Israel
Tel Aviv
Nucleai

Nucleai is Leading the Spatial Biology Revolution in Precision Medicine Join Us in Biomarker Discovery!

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.

04/11/2025

We’re pleased to announce results from our collaborative work with Bio-Techne and Lunaphore, featuring new data from the SECOMBIT clinical trial to be shared at he Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

The study demonstrates how Nucleai’s AI-powered multimodal platform, combined with Bio-Techne’s high-plex spatial biology technology, can identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies.

By integrating high-plex spatial proteomics with AI-driven multimodal analysis, the research translates complex tumor data into actionable insights for drug development and diagnostics.

We’re honored that this research was selected among the top 150 abstracts at this year’s meeting, underscoring the meaningful progress in applying spatial biology and AI to advance precision medicine.
Read the full press release👉 https://bit.ly/4oVkk4D

28/10/2025

In recognition of Breast Cancer Awareness Month, we’re highlighting some of our recent case studies and presentations focused on advancing biomarker discovery and patient stratification in breast cancer.

Targeted therapies like antibody-drug conjugates (ADCs) hold great promise, but identifying which patients will truly benefit remains a key challenge.

💡 Explore our latest resources:
🔹 AI-aided HER2 Ultralow Scoring to Enable Accurate Patient Stratification for ADCs
https://hubs.li/Q03QGs0R0

🔹 AI-augmented Scoring of the Bystander Effect for Effective ADC Patient Selection
https://hubs.li/Q03QGrRH0

🔹 Unleashing the Power of Computational Pathology – Pathology Visions 2025 Poster Presentation
https://hubs.li/Q03QGrXl0

🎗️ These studies, alongside other ongoing work at Nucleai, help drive a deeper understanding of breast cancer biology and support more informed treatment decisions.

24/10/2025

Innovation in healthcare doesn’t move at the speed of computation - it moves at the speed of verification.
Read our CEO, Avi Veidman’s latest post to learn why verification speed is critical to innovation in life science and health tech - and what we can do today to accelerate it.
🔗https://hubs.li/Q03Q3XWy0

22/10/2025

The countdown is on! We’re gearing up for World ADC 2025. Visit us at Booth #32 to discover how AI Pathology and Spatial Biomarker Solutions can advance ADC drug development and enhance your biomarker strategy.

Don’t miss our Head of Pathology, Dr. Ken Bloom, presenting:
Talk: 𝗡𝗼𝘃𝗲𝗹 𝗔𝗜 𝗦𝗽𝗮𝘁𝗶𝗮𝗹 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝘁𝗼 𝗜𝗻𝗳𝗼𝗿𝗺 𝗬𝗼𝘂𝗿 𝗔𝗗𝗖 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆
📅 Tuesday, November 4, 2025 | 2:30 PM PT

Let’s connect in San Diego to explore how AI spatial proteomics and OD-based quantitative scoring of IHC assays can accelerate your ADC programs.

Book a meeting: https://hubs.ly/Q03PMtvV0

17/10/2025

starts this Sunday and we’re bringing AI-powered spatial biomarkers and diagnostics to the forefront to improve clinical decision-making and patient outcomes.
Let’s meet in Las Vegas. Book a meeting: https://hubs.li/Q03P8R5X0

16/10/2025

Targeted therapies have transformed breast cancer care, yet not all biomarker-positive patients respond to treatment.

Nucleai’s AI spatial solutions provide deeper insights into tumor biology to support more personalized and effective treatment decisions in breast cancer.

🎗️ In recognition of Breast Cancer Awareness Month, we continue to support efforts that advance more personalized care.

Learn more https://hubs.li/Q03NWWDW0

15/10/2025

Can spatial biology reveal why some patients don’t respond to immunotherapy?
Join Dr. Ettai Markovits as he shares new evidence of a predictive metabolic signature linked to immunotherapy resistance.

🎥 Watch the full webinar on demand: https://bit.ly/4ob7kbb

08/10/2025

We’re honored to be named one of the Top 10 Companies of 2025 by Genetic Engineering & Biotechnology News for the third year in a row.

This year marks an especially meaningful milestone as we launched our first-of-its-kind deep learning model to automate the normalization of high-plex imaging data and showcased our OD-based quantitative biomarker scoring solution, advancing biomarker discovery for ADCs, bispecifics, and immunotherapies and making spatial biology more actionable for clinical and translational research.

A big thank-you to our team, partners, and collaborators driving innovation forward.

https://bit.ly/3VY11Ls

26/09/2025

We’re excited to bring AI-powered spatial biomarkers and diagnostics to the forefront, improving clinical decision-making and transforming patient outcomes.
Our CEO & Co-Founder, Avi Veidman, will be in Las Vegas for HLTH 2025.
:date: Going to HLTH? Let’s connect! https://hubs.li/Q03L8rMP0

24/09/2025

𝐇𝐨𝐰 𝐜𝐚𝐧 𝐰𝐞 𝐛𝐞𝐭𝐭𝐞𝐫 𝐩𝐫𝐞𝐝𝐢𝐜𝐭 𝐰𝐡𝐢𝐜𝐡 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐥𝐥 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐟𝐫𝐨𝐦 𝐇𝐄𝐑2-𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐀𝐃𝐂𝐬?
A new 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 study demonstrates how combining spatial biomarkers with an AI-powered approach could identify novel markers of efficacy—helping to stratify patients and guide treatment decisions.
In our latest blog, we break down the findings and share how Nucleai is redefining ADC research with high-resolution, optical density-based IHC quantification and spatial analysis capabilities that provide deeper insights into how ADCs work, why resistance may occur, and which patients are most likely to benefit.

👉 Read the full blog: https://hubs.ly/Q03KQFnH0

22/09/2025

🚀 Excited to kick off World CB & CDx tomorrow in Boston!

We’re looking forward to connecting with you and sharing how AI spatial proteomics can support ADC programs and help advance next-generation therapeutics.

📍 Booth #11 | 👉 Book a meeting: https://bit.ly/4msfeeg

💡 Don’t miss Dr. Ken Bloom’s talk — Sept 25 at 11:00 AM.
𝗡𝗼𝘃𝗲𝗹 𝗔𝗗𝗖 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗜𝗻𝗳𝗼𝗿𝗺 𝗬𝗼𝘂𝗿 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 & 𝗖𝗗𝘅 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆
Abstract Highlights:
✔️New research on how an antibody-drug conjugate (ADC) can bypass internalization, leading to the bystander effect
✔️How the tumor microenvironment and immune interactions could influence patient stratification and ADC-immunotherapy combo strategies
✔️How AI spatial proteomics and IHC, H&E-based quantitative biomarker scoring can give deeper insights into the MOA and efficacy of ADCs

21/09/2025

Wishing everyone celebrating a Shanah Tovah — a sweet and meaningful New Year. Thank you to our team, partners, and clients for your continued trust and support. 🍎🍯
שנה טובה ומתוקה!

Address

עין זיתים 4 תל אביב, ישראל
Tel Aviv
67013

Website

http://nucleai.ai/

Alerts

Be the first to know and let us send you an email when Nucleai posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Nucleai:

Shortcuts

Want your business to be the top-listed Computer & Electronics Service in Tel Aviv?